---
title: Biotechnology investments and financial risks
videoId: cwpGBCjpJiU
---

From: [[artedeinvertir]] <br/> 

Billionaire Bill Gates appears to be preparing for a new crisis, similar to past experiences, by acquiring stocks in companies that produce vaccines <a class="yt-timestamp" data-t="00:00:05">[00:00:05]</a>. This represents a significant shift in his [[economic_risks_and_investment_strategies | investment strategy]] <a class="yt-timestamp" data-t="00:00:23">[00:00:23]</a>, raising questions about his outlook on the future <a class="yt-timestamp" data-t="00:02:02">[00:02:02]</a>. His four favorite stocks within this new strategy are being closely analyzed, as their success could significantly increase his wealth <a class="yt-timestamp" data-t="00:00:28">[00:00:28]</a>.

## Bill Gates' Investment Acumen

Bill Gates played a crucial role during the last crisis, having previously warned about the likelihood of a pandemic and the world's unpreparedness <a class="yt-timestamp" data-t="00:00:47">[00:00:47]</a>. His deep knowledge of the biotechnology sector allowed him to predict which company would first develop a successful vaccine <a class="yt-timestamp" data-t="00:00:58">[00:00:58]</a>. With a fortune exceeding $100 billion, Gates is also recognized for his excellent results in the field of investment <a class="yt-timestamp" data-t="01:19:00">[01:19:00]</a>. Millions of investors follow his movements and statements due to his accurate vision of the future of the economy and stocks <a class="yt-timestamp" data-t="01:24:00">[01:24:00]</a>.

## Transparency in Investments

In the United States, stock market transparency rules mandate that institutional investors managing over $100 million in assets must periodically report their stock purchases and sales to the American regulator (SEC) <a class="yt-timestamp" data-t="02:11:00">[02:11:00]</a>. This public information allows insight into Bill Gates' vision for the future of the economy and the [[stock_market_risks_and_strategies | stock market]] <a class="yt-timestamp" data-t="02:23:00">[02:23:00]</a>.

## The Gates Foundation Portfolio Shift

Bill Gates primarily utilizes two investment vehicles: a fund for traditional, safer shares and the portfolio of the Bill & Melinda Gates Foundation, which is the focus of his new [[economic_risks_and_investment_strategies | investment strategy]] <a class="yt-timestamp" data-t="02:34:00">[02:34:00]</a>. His investment portfolio, recently made public, shows a radical shift in strategy, with 70% of his investments concentrated in just three vaccine-producing stocks <a class="yt-timestamp" data-t="01:43:00">[01:43:00]</a>. This concentration in BioNTech, CureVac, and Vir Biotechnology accounts for over 70% of his foundation's portfolio <a class="yt-timestamp" data-t="02:53:00">[02:53:00]</a>.

## Rationale for the Shift: Second-Generation Vaccines

These three companies are leading the development of "second-generation vaccines," which are expected to be more sophisticated and effective against current problems <a class="yt-timestamp" data-t="03:03:00">[03:03:00]</a>. In a CNN interview, Bill Gates highlighted the insufficient provision of quality vaccines to poorer countries by richer nations, leading to the resurgence of variants in wealthier countries <a class="yt-timestamp" data-t="03:27:00">[03:27:00]</a>. This situation necessitates the development of these second-generation vaccines, which Gates is integrating into his portfolio <a class="yt-timestamp" data-t="03:47:00">[03:47:00]</a>. He stated that a return to normalcy depends on the next generation of vaccines, and many companies are working towards this goal <a class="yt-timestamp" data-t="08:58:00">[08:58:00]</a>.

## Risks and Rewards of Biotechnology Investments

Investing in biotechnology companies during their development phase can be very risky and volatile, requiring a high level of knowledge to succeed <a class="yt-timestamp" data-t="04:01:00">[04:01:00]</a>. The number of failed clinical trials is high <a class="yt-timestamp" data-t="04:10:00">[04:10:00]</a>. However, successful ventures can yield very high financial rewards <a class="yt-timestamp" data-t="04:14:00">[04:14:00]</a>.

*   **BioNTech (BNTX):** In collaboration with Pfizer, BioNTech was the first company to develop an effective vaccine <a class="yt-timestamp" data-t="04:19:00">[04:19:00]</a>. Its shares rose from $90 to over $350 after satisfactory clinical trials <a class="yt-timestamp" data-t="04:25:00">[04:25:00]</a>.
*   **Moderna (MRNA):** Positioned as a leading developer of new vaccines, Moderna's shares increased from $70 to over $400 in less than 12 months <a class="yt-timestamp" data-t="04:38:00">[04:38:00]</a>.

## Key Biotechnology Stocks in Bill Gates' Portfolio

### BioNTech (BNTX)

*   **Ticker:** BNTX <a class="yt-timestamp" data-t="05:13:00">[05:13:00]</a>
*   **Price:** Approximately $360 per share <a class="yt-timestamp" data-t="05:17:00">[05:17:00]</a>
*   **Bill Gates' Investment:** A "star investment," Gates began investing in BioNTech in late 2019, six months before the crisis <a class="yt-timestamp" data-t="05:21:00">[05:21:00]</a>. His initial $50 million investment is now valued at over $200 million <a class="yt-timestamp" data-t="05:28:00">[05:28:00]</a>.
*   **Outlook:** BioNTech, along with Pfizer, launched the first effective vaccine <a class="yt-timestamp" data-t="05:33:00">[05:33:00]</a>. The company projects a demand for one million doses per year from 2022 onwards, indicating a potentially recurrent business <a class="yt-timestamp" data-t="05:43:00">[05:43:00]</a>. For the current year, the company is estimated to earn over $37 per share, trading below 10 times earnings, which is an attractive price for a biotechnology company <a class="yt-timestamp" data-t="06:00:00">[06:00:00]</a>. If the business proves recurrent, shares could more than double, with further potential from successful new clinical trials <a class="yt-timestamp" data-t="06:12:00">[06:12:00]</a>.

### CureVac (CVAC)

*   **Ticker:** CVAC <a class="yt-timestamp" data-t="06:30:00">[06:30:00]</a>
*   **Price:** Approximately $70 per share <a class="yt-timestamp" data-t="06:34:00">[06:34:00]</a>
*   **Bill Gates' Investment:** Gates invested in CureVac in 2015 with a small $50 million investment, which now totals over $230 million <a class="yt-timestamp" data-t="06:41:00">[06:41:00]</a>.
*   **Outlook:** CureVac, a German company, is collaborating with large pharmaceutical companies like GlaxoSmithKline on second-generation vaccines <a class="yt-timestamp" data-t="06:52:00">[06:52:00]</a>. Unlike BioNTech, CureVac is still in the development phase, making its investment more speculative and volatile <a class="yt-timestamp" data-t="07:03:00">[07:03:00]</a>. It is not yet profitable and its success heavily depends on its ongoing clinical trials <a class="yt-timestamp" data-t="07:08:00">[07:08:00]</a>.

### Vir Biotechnology (VIR)

*   **Ticker:** VIR <a class="yt-timestamp" data-t="07:40:00">[07:40:00]</a>
*   **Price:** Approximately $48 per share <a class="yt-timestamp" data-t="07:41:00">[07:41:00]</a>
*   **Bill Gates' Investment:** Gates demonstrated good judgment by investing in this highly innovative company in 2019 <a class="yt-timestamp" data-t="07:44:00">[07:44:00]</a>.
*   **Outlook:** Vir Biotechnology is developing an effective solution against multiple variants, including the Delta variant, with over 82% effectiveness <a class="yt-timestamp" data-t="07:52:00">[07:52:00]</a>. An additional factor of interest is its development of an inhaled vaccine solution, which could simplify application and encourage greater public participation <a class="yt-timestamp" data-t="08:07:00">[08:07:00]</a>. Similar to CureVac, Vir Biotechnology is in the development phase and is not yet profitable, making it a highly speculative [[opportunities_and_risks_in_stock_market_investing | stock opportunity]] with high risk but also high potential reward <a class="yt-timestamp" data-t="08:20:00">[08:20:00]</a>.

These [[stock_opportunities_in_healthcare_and_technology_sectors | investment opportunities]] in biotechnology align with Bill Gates' belief that the development of next-generation vaccines is crucial for humanity to return to normalcy and can generate high returns for shareholders <a class="yt-timestamp" data-t="09:09:00">[09:09:00]</a>.